Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma

Cancer Immunology, Immunotherapy

Volumn 56, Issue 8, 2007, Pages 1299-1309

  Kamstock, Debra ^a   Elmslie, Robyn ^b   Thamm, Douglas ^a   Dow, Steven ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b NONE

Author keywords

Antibodies; Cancer; Canine; Endothelial cell; Immunization

Indexed keywords

CANCER VACCINE; RECOMBINANT VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITY; DOG; DRUG TOLERABILITY; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOFT TISSUE SARCOMA; TREATMENT DURATION; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; CANCER VACCINES; DOG DISEASES; DOGS; DRUG EVALUATION; FEMALE; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; MALE; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; SARCOMA; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34248592407     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0282-7     Document Type: Article

References (41)

1. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl. 3):4-10
2. Millanta F, Silvestri G, Vaselli C, Citi S, Pisani G, Lorenzi D et al (2006) The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. Res Vet Sci 81:354-357
3. Parikh AA, Ellis LM (2004) The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am 18(5):951-971, vii
4. Benouchan M, Colombo BM (2005) Anti-angiogenic strategies for cancer therapy (review). Int J Oncol 27(2):563-571
5. Cao Y (2004) Antiangiogenic cancer therapy. Semin Cancer Biol 14(2):139-145
6. Cardones AR, Banez LL (2006) VEGF inhibitors in cancer therapy. Curr Pharm Des 12(3):387-394
7. Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69(Suppl. 3):11-16
8. Glade-Bender J, Kandel JJ, Yamashiro DJ (2003) VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3(2):263-276
9. Verheul HM, Pinedo HM (2005) Inhibition of angiogenesis in cancer patients. Expert Opin Emerg Drugs 10(2):403-412
10. Zhang HT, Bicknell R (2003) Therapeutic inhibition of angiogenesis. Mol Biotechnol 25(2):185-200
11. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al (2004) Bevacizumab plus irinotecan, Xuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
12. Hurwitz H, Kabbinavar F (2005) Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 69(Suppl. 3):17-24
13. Salesi N, Bossone G, Veltri E, Di Cocco B, Marolla P, Pacetti U, et al (2005) Clinical experience with bevacizumab in colorectal cancer. Anticancer Res 25(5):3619-3623
14. Sanborn RE, Sandler AB (2006) The safety of bevacizumab. Expert Opin Drug Saf 5(2):289-301
15. Rafii S (2002) Vaccination against tumor neovascularization: promise and reality. Cancer Cell 2(6):429-431
16. Moniz M, Yeatermeyer J, Wu TC (2005) Control of cancers by combining antiangiogenesis and cancer immunotherapy. Drugs Today (Barc) 41(7):471-494
17. Li Y, Bohlen P, Hicklin DJ (2003) Vaccination against angiogenesis-associated antigens: a novel cancer immunotherapy strategy. Curr Mol Med 3(8):773-779
18. Reisfeld RA, Niethammer AG, Luo Y, Xiang R (2004) DNA vaccines designed to inhibit tumor growth by suppression of angiogenesis. Int Arch Allergy Immunol 133(3):295-304
19. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, et al (2001) Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 98(20):11545-11550
20. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, et al (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8(12):1369-1375
21. Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, et al (2003) Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102(5):1815-1823
22. Lu F, Qin ZY, Yang WB, Qi YX, Li YM (2004) A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo. World J Gastroenterol 10(14):2039-2044
23. Keke F, Hongyang Z, Hui Q, Jixiao L, Jian C (2004) A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer. Cancer Biother Radiopharm 19(5):649-657
24. Luo Y, Wen YJ, Ding ZY, Fu CH, Wu Y, Liu JY, et al (2006) Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin Cancer Res 12(6):1813-1819
25. Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE, Fortier AH (2000) Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 19(9-10):1294-1303
26. Scappaticci FA, Nolan GP (2003) Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine. Anticancer Res 23(2B):1165-1172
27. Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, et al (2004) Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 95(1):85-90
28. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, et al (2000) Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6(10):1160-1166
29. Vail DM, MacEwen EG (2000) Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18(8):781-792
30. Porrello A, Cardelli P, Spugnini EP (2006) Oncology of companion animals as a model for humans. An overview of tumor histotypes. J Exp Clin Cancer Res 25(1):97-105
31. Clifford CA, Hughes D, Beal MW, Mackin AJ, Henry CJ, Shofer FS, et al (2001) Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma. J Vet Intern Med 15(2):131-135
32. Scheidegger P, Weiglhofer W, Suarez S, Kaser-Hotz B, Steiner R, Ballmer-Hofer K, et al (1999) Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs. Biol Chem 380(12):1449-1454
33. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, et al (2006) Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 176(12):7335-7345
34. Mueller RS, Veir J, Fieseler KV, Dow SW (2005) Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study. Vet Dermatol 16(1):61-68
35. Walter CU, Biller BJ, Lana SE, Bachand AM, Dow SW (2006) Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med 20(2):342-347
36. Wergin MC, Kaser-Hotz B (2004) Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours. In Vivo 18(1):15-19
37. Kamstock D, Guth A, Elmslie R, Kurzman I, Liggitt D, Coro L, et al (2006) Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 13(3):306-317
38. Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, Zhang X, et al (2005) Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 11(9):992-997
39. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3(12 Pt 1):2187-2190
40. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, et al (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77(6):956-964
41. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE (1998) Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 94(4):395-404